Cell line · CVCL_1629
Papers137
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 137
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor FAK supports fibrillar collagen expression in ovarian cancer ascites. | Matrix Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Two-step PEG-based surface functionalization of gold nanoparticles enables specific SERS imaging of EGFR in an ovarian cancer cell model. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Paclitaxel induces NM2-dependent cellular contraction through GEF-H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Interferon beta drives therapy resistance in a patient-derived model of high-grade serous ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Self-assembled verteporfin nanoparticles decrease drug efflux by P-glycoprotein without light activation in drug-resistant cancer cells. | Bioeng Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Disruption of the SNRPF-DDX24-E2F4 Feedback Loop Uncouples Splicing and Transcriptional Regulation to Suppress Ovarian Cancer Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. | Genome Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anticancer Potential of Piericidin A1 and Derivatives Isolated From Streptomyces sp. Associated With Palythoa variabilis From Brazilian Reefs. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Global analysis of cancer cell responses to USP9X inhibition. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer. | Device | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1629/papers